MedTrace Logo

Study of Blood Immune Cells in Cancer Patients Compared to Controls

NCT01312701 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-03-11

No results posted yet for this study

Summary

Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can:

* be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means
* may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy
* are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types

Conditions

  • Solid Carcinoma

Sponsors & Collaborators

  • Hebrew University of Jerusalem

    collaborator OTHER

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Hovav Nechushtan, MD PhD · Oncology Dept Hadassah Hebrew University Medical Center

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-03-31
Completion
2013-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01312701 on ClinicalTrials.gov